Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma.

Blood Adv · 2023 · PMC10758726 · PMID 37603594

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

marginally significantP value = .06so close (0.05 < p ≤ 0.1)

Alternatively, when comparing patients with full intended dose of BV with those with any dose reduction of BV, the latter had better PFS rates, and this difference in PFS was marginally significant ( P value = .06; supplemental Figure 1 in the supplemental Appendix ).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.